Evidence map›Paper›PMID 27790858›Full record

ArticleCancer medicine2016

Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia.

Julian Lindsay, Masrura Kabir, Nicole Gilroy, Gemma Dyer, Lisa Brice, John Moore, Matthew Greenwood, Mark Hertzberg, David Gottlieb, Stephen R Larsen and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Julian LindsayDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID 0000-0002-7086-538X
Masrura KabirWestmead Hospital, Sydney, New South Wales, Australia.
Nicole GilroyWestmead Hospital, Sydney, New South Wales, Australia.
Gemma DyerCancer Institute NSW, Sydney, New South Wales, Australia.
Lisa BriceDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
John MooreDepartment of Haematology, St Vincents Hospital, Sydney, New South Wales, Australia.
Matthew GreenwoodDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Mark HertzbergDepartment of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
David GottliebWestmead Hospital, Sydney, New South Wales, Australia.
Stephen R LarsenInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Megan HoggWestmead Hospital, Sydney, New South Wales, Australia.
Louisa BrownDepartment of Haematology, Calvary Mater Newcastle, Sydney, New South Wales, Australia.
Gillian HuangWestmead Hospital, Sydney, New South Wales, Australia.
Jeff TanDepartment of Haematology, St Vincents Hospital, Sydney, New South Wales, Australia.
Christopher WardDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Ian KerridgeDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
The University of Sydney · AUWestmead Hospital · AURoyal North Shore Hospital · AUSt Vincent's Hospital Sydney · AUCalvary Mater Newcastle Hospital · AUCancer Institute of New South Wales · AUPrince of Wales Hospital · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402-item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind-body therapy (17.2%), herbal supplements (13.5%), manipulative and body-based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population.

Indexed as

Complementary TherapiesHematopoietic Stem Cell TransplantationAdultAgedAustraliaFemaleHumansLeukemiaMaleMiddle AgedPatient Acceptance of Health CarePopulation SurveillanceSocioeconomic FactorsSurvivorsTransplantation, HomologousBlood and marrow transplantation (BMT)complementary and alternative medicine (CAM)hematopoietic stem cell transplantation (HSCT)quality of lifesurvivors

Identifiers

PMID27790858
PMCPMC5224858
OpenAlexW2539627938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.